Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
20mg) of its lead product candidate, buntanetap, for treating Parkinson's disease (PD). Per the company, treatment with the candidate demonstrated a safe and effective improvement in motor and non-motor activities and improved cognitive functions in patients with early PD. Annovis' shares surged 76.1% on Jul 2 following the encouraging news. Buntanetap, an orally available small molecule, has a unique mechanism of action that allows the candidate to reverse neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. Please note that the phase III study was completed in December 2023, with an original plan for data announcement in the first quarter of 2024. Due to a delay in the process of organizing and cleaning data, Annovis announced the unblinding of the phase III PD study data in May 2024 followed by the top-line efficacy and safety data in the latest press release. It was observed that patients who w
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and MorePR Newswire
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative DiseasesGlobeNewswire
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative CombinationsGlobeNewswire
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 9/30/24 - Form 8-K
- 8/15/24 - Form 8-K
- 8/14/24 - Form 10-Q
- ANVS's page on the SEC website